Megapharm Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Megapharm Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013958
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イスラエル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Megapharm Ltd (Megapharm) is a biotechnology company which offers marketing services. It is engaged in marketing of pharmaceutical products for international companies. Megapharm markets a wide range of products in various therapeutic areas such as dermatology, gastroenterology, central nervous system, oncology, rheumatology, urology, respiratory and allergy, and gynaecology, among others. The company also provides clinical research services such as regulatory guidance, safety reporting, clinical monitoring, drug import and storage. It also provides consultation and supervision services to its partners associated with the clinical studies in Israel. The company has partners in Germany, Switzerland, Ireland, Cyprus, Austria and the UK, among others. Megapharm is headquartered in Raanana, Israel.

Megapharm Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Megapharm Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Megapharm Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Megapharm Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Megapharm Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Megapharm Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Megapharm Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Pharming Enters Into Co-Marketing Agreement With Megapharm For Ruconest 10
Licensing Agreements 11
Megapharm Enters into Licensing Agreement with MolMed for Zalmoxis 11
Megapharm Enters into Licensing Agreement with XBiotech for Xilonix 12
Vanda Pharma Enters Into Licensing Agreement With MegaPharm For Fanapt 13
Megapharm Ltd – Key Competitors 14
Megapharm Ltd – Key Employees 15
Megapharm Ltd – Locations And Subsidiaries 16
Head Office 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Megapharm Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Megapharm Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Megapharm Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Megapharm Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Megapharm Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Megapharm Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Pharming Enters Into Co-Marketing Agreement With Megapharm For Ruconest 10
Megapharm Enters into Licensing Agreement with MolMed for Zalmoxis 11
Megapharm Enters into Licensing Agreement with XBiotech for Xilonix 12
Vanda Pharma Enters Into Licensing Agreement With MegaPharm For Fanapt 13
Megapharm Ltd, Key Competitors 14
Megapharm Ltd, Key Employees 15

★海外企業調査レポート[Megapharm Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ngai Hing Hong Company Ltd (1047):企業の財務・戦略的SWOT分析
    Ngai Hing Hong Company Ltd (1047) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Pentair plc:企業の戦略・SWOT・財務情報
    Pentair plc - Strategy, SWOT and Corporate Finance Report Summary Pentair plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Aprea AB-製薬・医療分野:企業M&A・提携分析
    Summary Aprea AB (Aprea) discovers and develops novel anticancer compounds targeting the tumor suppressor protein p53. The company’s lead drug candidate includes APR-246, an anti-cancer compound that targets and reactivates the tumor suppressor protein p53, inducing programmed cell death in many hum …
  • Green Plains Inc (GPRE):企業の財務・戦略的SWOT分析
    Green Plains Inc (GPRE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Dil Ltd (506414):企業の財務・戦略的SWOT分析
    Summary Dil Ltd (Dil), formerly Duphar-Interfran Ltd, is a developer of medicinal and pharmaceutical products. The company offers products in the areas such as biotechnology, environmental solutions, pharmaceuticals, and vitamins. It also offers services such as health and wellness, entertainment, e …
  • MedMira Inc (MIR)-医療機器分野:企業M&A・提携分析
    Summary MedMira Inc (MedMira) is a medical device company that offers rapid diagnostics and technology solutions. The company offers products in areas of HIV, H. pylori, syphilis, multiplex, miriad rvf toolkit, and tissue and eye banks. It offers testing products for HIV, H. Pylori and syphilis, bes …
  • Cidara Therapeutics Inc (CDTX):企業の財務・戦略的SWOT分析
    Summary Cidara Therapeutics Inc (Cidara), formerly K2 Therapeutics Inc is a biotechnology company that discovers, develops and commercializes novel anti-infectives including immunotherapies. The company's pipeline products include CD101 for treatment of invasive fungal disease; and CD377 for treatin …
  • Sonatrach SPA-石油・ガス分野:企業M&A・提携分析
    Summary Sonatrach SPA (Sonatrach) is a state-owned integrated oil and gas company. Its businesses include exploration and production; pipeline transportation; liquefaction, refining and petrochemicals; marketing of petroleum products; maritime transportation; and other services. The company explores …
  • Medytox Inc (086900):企業の財務・戦略的SWOT分析
    Summary Medytox Inc (Medytox) develops, manufactures and markets biopharmaceutical products. Its products include botulinum toxin type A product, hyaluronic acid filler, medical devices, prescription cream, toxin detection kits and antitoxin therapeutics for treating skin disorders. The company is a …
  • Peter’s Food Service Ltd:企業の戦略・SWOT・財務情報
    Peter's Food Service Ltd - Strategy, SWOT and Corporate Finance Report Summary Peter's Food Service Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Range Resources Corp (RRC):石油・ガス:M&Aディール及び事業提携情報
    Summary Range Resources Corp (Range) is independent oil, natural gas and natural gas liquids (NGL) company that explores, develops, and acquires natural gas and oil properties in the US. It has oil and gas properties in the Appalachian basin and Northern Louisiana of the US. Range’s natural gas and …
  • Spicers Ltd:企業の戦略的SWOT分析
    Spicers Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Fenner PLC (FENR):企業の財務・戦略的SWOT分析
    Summary Fenner PLC (Fenner) a subsidiary of Michelin SCA, is a provider of reinforced polymer technology. The company operates in the areas of advanced engineered products and engineered conveyor solutions. Its product portfolio includes heavyweight conveyor belt, high performance polymer components …
  • Perenco Holdings:企業の戦略的SWOT分析
    Perenco Holdings - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Ringier AG:企業の戦略的SWOT分析
    Ringier AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Claverack Rural Electric Cooperative Inc:企業の戦略的SWOT分析
    Claverack Rural Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Petrol dd Ljubljana (PETG):石油・ガス:M&Aディール及び事業提携情報
    Summary Petrol dd Ljubljana (Petrol dd) is an energy company. It markets and distributes oil and petroleum products, electricity, heat, merchandise, natural gas and liquefied petroleum gas (LPG). The company sells automotive products, foodstuffs, accessories, tobacco, and chemical products. Petrol d …
  • Li Ning Company Ltd (2331):企業の財務・戦略的SWOT分析
    Li Ning Company Ltd (2331) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Altimmune Inc-製薬・医療分野:企業M&A・提携分析
    Summary Altimmune Inc (Altimmune), formerly Vaxin Inc is a biotechnology company that develops vaccines and other biological products. The company's products include novel vaccine delivery platforms, immunotherapeutic products, intranasally administered recombinant influenza vaccine, traditional inf …
  • VistaGen Therapeutics Inc (VTGN):医療機器:M&Aディール及び事業提携情報
    Summary VistaGen Therapeutics Inc (VistaGen) is a clinical stage biopharmaceutical company that develops new generation medicines for depression and neuropsychiatric disorders. The company’s pipeline product, AV-101, currently under Phase 2 clinical development, is an oral N-methyl-D-aspartate recep …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆